Used in cancer immunotherapy to block the TIGIT receptor on immune cells, enhancing the body's immune response against tumors. By inhibiting TIGIT, this antibody helps restore T cell and natural killer (NK) cell activity, which can be suppressed in the tumor microenvironment. It is being investigated in clinical trials, often in combination with other immune checkpoint inhibitors like anti-PD-1/PD-L1 therapies, to improve outcomes in various solid tumors including non-small cell lung cancer and other advanced cancers. Its primary role is as a reference standard in preclinical and analytical studies to support the development of anti-TIGIT therapeutics.